small molecule

DOVONEX

CALCIPOTRIENE

Loss of exclusivityloss of exclusivity
CompanyLEO PHARMA AS

Drug detail

Brand nameDOVONEX
Active ingredientCALCIPOTRIENE
Strength0.005% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
Dosage formOINTMENT
RouteTOPICAL
ModalitySmall molecule
FDA approvalDecember 1993
Marketing statusRX

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

DOVONEX patent cliff — loss of exclusivity — | CliffBio